NOVELTY - Preparation (P1) of nebivolol hydrochloride (I), involves: treating benzylamine with 6-fluoro-2-(oxiran-2-yl)chroman in suitable solvent; isolating 2-benzylamino-1-(6-fluoro-chroman-2-yl)-ethanol (II); condensing (II) with 6-fluoro-2-oxiranyl-chroman in organic solvent; forming 2-(benzyl-(2-(6-fluoro-chroman-2-yl)-2-hydroxy-ethyl)-amino)-1-(6-fluoro-chroman-2-yl)-ethanol (III) in-situ; deprotecting (III) by catalytic hydrogenation in autoclave to form nebivolol free base; treating the base with alcoholic hydrochloric acid; and purifying pure nebivolol hydrochloride (I).    USE - For preparation of nebivolol hydrochloride (claimed) used for the treatment of hypertension.    ADVANTAGE - The method is an efficient, improved and industrially applicable process for preparation of nebivolol hydrochloride which is conveniently applicable to industrial scale; avoid use of hazardous reagents and isolation of intermediates at various stages as well makes the process plant friendly and economically viable; and prepares nebivolol hydrochloride consisting ratio of d-nebivolol and d-nebivolol of 48.5-51.5% with total chiral purity of greater than or equal to 99%.    DETAILED DESCRIPTION - An improved process (P1) for the preparation of nebivolol hydrochloride (I) comprising the ratio of d-nebivolol and d-nebivolol of 48.5-51.5%, involves: a) treating benzylamine with 6-fluoro-2-(oxiran-2-yl)chroman in suitable solvent; b) isolating 2-benzylamino-1-(6-fluoro-chroman-2-yl)-ethanol (II); c) condensing (II) with 6-fluoro-2-oxiranyl-chroman in an organic solvent; d) forming 2-(benzyl-(2-(6-fluoro-chroman-2-yl)-2-hydroxy-ethyl)-amino)-1-(6-fluoro-chroman-2-yl)-ethanol (III) in-situ; e) deprotecting (III) in situ by catalytic hydrogenation in autoclave to form nebivolol free base; f) treating nebivolol free base in situ with alcoholic hydrochloric acid; g) isolating technical nebivolol hydrochloride; and h) purifying technical nebivolol hydrochloride in suitable solvent to get pure nebivolol hydrochloride (I). INDEPENDENT CLAIMS are included for the following:    (1) preparation (P2) of 2-benzylamino-1-(6-fluoro-chroman-2-yl)-ethanol (II), involving: a1) providing 6-fluoro-2-(oxiran-2-yl)chroman in a suitable solvent; b1) providing benzylamine in a suitable solvent; c1) adding solution of step a1) into solution of step b1) drop wise or lot wise; and d1) isolating 2-benzylamino-1-(6-fluoro-chroman-2-yl)-ethanol (II);    (2) an in-situ process (P3) for the preparation of technical nebivolol hydrochloride, involving: condensing 2-benzylamino-1-(6-fluoro-chroman-2-yl)-ethanol (II) with 6-fluoro-2-oxiranyl-chroman in an organic solvent; forming 2-(benzyl-(2-(6-fluoro-chroman-2-yl)-2-hydroxy-ethyl)-amino)-1-(6-fluoro-chroman-2-yl)-ethanol (III); deprotecting 2-(benzyl-(2-(6-fluoro-chroman-2-yl)-2-hydroxy-ethyl)-amino)-1-(6-fluoro-chroman-2-yl)-ethanol (III) by catalytic hydrogenation in autoclave to form nebivolol free base; treating formed nebivolol free base with alcoholic hydrochloric acid in different reaction vessel; and isolating technical nebivolol hydrochloride;    (3) purification (P4) of technical nebivolol hydrochloride, involving: dissolving technical nebivolol hydrochloride in methanol; refluxing the reaction mixture; filtering the reaction mixture; distilling methanol; cooling at temperature 37-39 degrees C; and isolating pure nebivolol hydrochloride (I);    (4) preparation (P5) of technical nebivolol hydrochloride, involving: providing reaction mixture of nebivolol free base in autoclave; transferring the reaction mixture into glass vessel from autoclave; adding alcoholic hydrochloric acid into reaction mixture; and isolating technical nebivolol hydrochloride; and    (5) new nebivolol hydrochloride consisting ratio of d-nebivolol and d-nebivolol of 48.5-51.5% with total chiral purity of greater than or equal to 99%.